12:00 AM
 | 
May 04, 2009
 |  BioCentury  |  Finance

Sequenom Chronicles

Sequenom Chronicles

Sequenom Inc. (NASDAQ:SQNM) fell 71% on the week after reporting after market close Wednesday that it delayed the expected June launch of its SEQureDx Trisomy 21 test for Down syndrome due to "employee mishandling" of data. The stock was up 108% in 2008 on...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >